Keywords: Europe, EMEA, Janssen-Cilag, Regranex, Johnson & Johnson, Cancer risk

EMEA recommends Janssen-Cilag’s Regranex not be used in patients with any pre-existing cancer

Article | 19 February 2010

Print This

Following a review of the available data on a possible risk of cancer in patients using Regranex (becaplermin), from Janssen-Cilag ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in